Dr. Alex Dulovic

Dr. Alex Dulovic joined the NMI in late 2020 as a Postdoc working on various SARS-CoV-2 projects. He became deputy group leader and then group leader for Multiplex Immunoassays in 2022 and 2024 respectively. As Senior Scientist of the BioDev Center, he works on developing novel assays to better understand adaptive and innate immune responses to infection and vaccination, together with academic, clinical and industrial partners.

Selected Publications

• Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nature Communications, 2021, DOI: 10.1038/-021-23473-6
• Robust and durable serological response following pediatric SARS-CoV-2 infection. Nature Communications, 2022, DOI: 10.1038/s41-27595-9
• Development and validation of a respiratory syncytial virus multiplex immunoassay. Infection, 2024, DOI: 10.1007-024-02180-6
• Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. Lancet Ebiomedicine, 2021, DOI: 10.1016/j.2021.103524
• In-depth analysis of serum antibodies against Epstein-Barr virus lifecycle proteins, and EBNA1, ANO2, GlialCAM and CRYAB peptides in patients with multiple sclerosis. Frontiers in Immunology, 2024, DOI: 10.3389/487523

ORCID: 0000-0003-0017-6738